Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes
- PMID: 29901421
- PMCID: PMC6110124
- DOI: 10.1089/dia.2018.0150
Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes
Abstract
Background: Frequent use of continuous glucose monitoring (CGM) systems is associated with improved glycemic outcomes in persons with diabetes, but the need for calibrations and sensor insertions are often barriers to adoption. In this study, we evaluated the performance of G6, a sixth-generation, factory-calibrated CGM system specified for 10-day wear.
Methods: The study enrolled participants of ages 6 years and up with type 1 diabetes or insulin-treated type 2 diabetes at 11 sites in the United States. Participation involved one sensor wear period of up to 10 days. Adults wore the system on the abdomen; youth of ages 6-17 years could choose to wear it on the abdomen or upper buttocks. Clinic sessions for frequent comparison with reference blood glucose measurements took place on days 1, 4-5, 7, and/or 10. Participants of ages 13 years and up underwent purposeful supervised glucose manipulation during in-clinic sessions. During the study, participants calibrated the systems once daily. However, analysis was performed on glucose values that were derived from reprocessed raw sensor data, independently of self-monitored blood glucose values used for calibration. Reprocessing used assigned sensor codes and a factory-calibration algorithm. Performance evaluation included the proportion of CGM values that were within ±20% of reference glucose values >100 mg/dL or within ±20 mg/dL of reference glucose values ≤100 mg/dL (%20/20), the analogous %15/15, and the mean absolute relative difference (MARD, expressed as a percentage) between temporally matched CGM and reference values.
Results: Data from 262 study participants (21,569 matched CGM reference pairs) were analyzed. The overall %15/15, %20/20, and MARD were 82.4%, 92.3%, and 10.0%, respectively. Matched pairs from 134 adults and 128 youth of ages 6-17 years were similar with respect to %20/20 (92.4% and 91.9%) and MARD (9.9% and 10.1%). Overall %20/20 values on days 1 and 10 of sensor wear were 88.6% and 90.6%, respectively. The system's "Urgent Low Soon" (predictive of hypoglycemia within 20 min) hypoglycemia alert was correctly provided 84% of the time within 30 min before impending biochemical hypoglycemia (<70 mg/dL). The 10-day sensor survival rate was 87%.
Conclusion: The new factory-calibrated G6 real-time CGM system provides accurate readings for 10 days and removes several clinical barriers to broader CGM adoption.
Keywords: Advanced algorithm; Clinical accuracy; Continuous glucose monitoring; Factory-calibrated; Glucose sensor performance; MARD.
Conflict of interest statement
R.P.W reports research support from Dexcom, Bigfoot Biomedical, MannKind Corporation, Novo Nordisk, Helmsley Charitable Trusty and NIH/NIDDK and advisory board consulting fees from Eli Lilly and Company.
L.M.L. has served as a consultant or on advisory boards for Lilly, NovoNordisk, Sanofi, Roche, Johnson & Johnson, Boehringer Ingelheim, AstraZeneca, Mannkind, Dexcom, Insulet, Senseonics, Unomedical, and Menarini.
V.N.S.' employer has received research support from the Sanofi US, Dexcom Inc, Eyenuk, and Jaeb Center for Health Research. V.N.S. served on advisory board of Sanofi US and received speaking fees from Dexcom Inc.
S.K.G. has received Advisory Board Consulting fees from Medtronic, Roche, Merck, Lexicon, Novo Nordisk, Sanofi, Mannkind, Senseonics, Zealand, and Eli Lilly. S.K.G. has received research grants through the University of Colorado Denver from Eli Lilly, Novo-Nordisk, Merck, Lexicon, Medtronic, Dario, NCI, T1D Exchange, NIDDK, JDRF, Animas, Dexcom, and Sanofi. S.K.G. does not own stocks in any device or pharmaceutical company.
Figures


Similar articles
-
Performance of a Factory-Calibrated Real-Time Continuous Glucose Monitoring System Utilizing an Automated Sensor Applicator.Diabetes Technol Ther. 2018 Jun;20(6):428-433. doi: 10.1089/dia.2018.0143. Diabetes Technol Ther. 2018. PMID: 29923775 Free PMC article.
-
Performance of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System in Pediatric Participants With Type 1 Diabetes.J Diabetes Sci Technol. 2019 Mar;13(2):254-258. doi: 10.1177/1932296818798816. Epub 2018 Sep 10. J Diabetes Sci Technol. 2019. PMID: 30198331 Free PMC article.
-
Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes.J Diabetes Sci Technol. 2022 Jan;16(1):70-77. doi: 10.1177/1932296820958754. Epub 2020 Sep 19. J Diabetes Sci Technol. 2022. PMID: 32954812 Free PMC article.
-
Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.Diabetes Technol Ther. 2017 Jun;19(S3):S25-S37. doi: 10.1089/dia.2017.0035. Diabetes Technol Ther. 2017. PMID: 28585879 Free PMC article. Review.
-
Personal continuous glucose monitoring (CGM) in diabetes management: review of the literature and implementation for practical use.Diabetes Res Clin Pract. 2012 Jun;96(3):294-305. doi: 10.1016/j.diabres.2011.12.010. Epub 2011 Dec 28. Diabetes Res Clin Pract. 2012. PMID: 22209014 Review.
Cited by
-
Bayesian denoising algorithm dealing with colored, non-stationary noise in continuous glucose monitoring timeseries.Front Bioeng Biotechnol. 2023 Nov 22;11:1280233. doi: 10.3389/fbioe.2023.1280233. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 38076424 Free PMC article.
-
Forecasting of Glucose Levels and Hypoglycemic Events: Head-to-Head Comparison of Linear and Nonlinear Data-Driven Algorithms Based on Continuous Glucose Monitoring Data Only.Sensors (Basel). 2021 Feb 27;21(5):1647. doi: 10.3390/s21051647. Sensors (Basel). 2021. PMID: 33673415 Free PMC article.
-
Analytical Performance of the FreeStyle Libre 2 Glucose Sensor in Healthy Male Adults.Sensors (Basel). 2024 Sep 5;24(17):5769. doi: 10.3390/s24175769. Sensors (Basel). 2024. PMID: 39275680 Free PMC article.
-
Review of methods for detecting glycemic disorders.Diabetes Res Clin Pract. 2020 Jul;165:108233. doi: 10.1016/j.diabres.2020.108233. Epub 2020 Jun 1. Diabetes Res Clin Pract. 2020. PMID: 32497744 Free PMC article. Review.
-
Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control.Diabetes Metab J. 2023 Jan;47(1):27-41. doi: 10.4093/dmj.2022.0271. Epub 2023 Jan 12. Diabetes Metab J. 2023. PMID: 36635028 Free PMC article. Review.
References
-
- Miller K, Foster N, DeSalvo D, et al. : Continuous glucose monitoring (CGM) use in type 1 diabetes: An update from the T1D exchange clinic registry. Pediatric Diabetes 2016;17(S24):49. - PubMed
-
- FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm602870.htm Accessed May14, 2018
-
- Clukey R, North B, Parkin C: Utilization of human factors analysis throughout product development enhances usability of CGM sensor applicators. Diabetes 2017;67(S1):A184
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous